May 29, 2025   SOURCE: PR NewsWire

Nextbiomedical Publishes Landmark Study in GUT Demonstrating Nexpowder(TM) Significantly Reduces Rebleeding After Endoscopic Hemostasis

SEOUL, South Korea, May 29, 2025 /PRNewswire/ -- Nextbiomedical announced today that its novel hemostatic powder, Nexpowder(TM), has been published in GUT (Impact Factor: 23), one of the world's most influential journals in gastroenterology. The large-scale randomized controlled trial (RCT) demonstrates that Nexpowder(TM) significantly reduces the risk of rebleeding following successful endoscopic hemostasis in patients with non-variceal upper gastrointestinal bleeding (NVUGIB).

The study, titled "Prevention of rebleeding after primary haemostasis using haemostatic powder in non-variceal upper gastrointestinal bleeding: a multicentre randomized controlled trial," was conducted across three leading university hospitals in South Korea. A total of 341 patients who achieved primary hemostasis were randomized to receive either standard therapy alone or standard therapy with the addition of Nexpowder(TM).

Key findings include:

    --  72-hour rebleeding rate: 2.9% in the Nexpowder(TM) group vs. 11.3% in
        the control group (p = 0.005)
    --  30-day cumulative rebleeding rate: 7.0% vs. 18.8% (p = 0.004)
    --  Ulcer subgroup (3-day rebleeding): 3.0% vs. 12.0% (p = 0.004)

Nexpowder(TM) is a proprietary powder-based hemostatic agent that adheres to bleeding lesions and forms a protective gel upon contact with moisture, creating an effective physical barrier. This design helps to prevent early and delayed rebleeding, particularly in high-risk lesions such as peptic ulcers.

In endoscopic hemostasis for non-variceal upper gastrointestinal bleeding (NVUGIB), the administration of proton pump inhibitors (PPIs) is a pharmacological approach to suppress gastric acid secretion and is included as a standard treatment in clinical guidelines. This is the first study to demonstrate a reduction in gastrointestinal rebleeding since PPIs were included in clinical guidelines, providing clinical evidence that Nexpowder(TM) may contribute to rebleeding prevention following endoscopic hemostasis.

Nexpowder(TM) as a first-in-class solution for rebleeding prevention," said the Chief Technology Officer of Nextbiomedical. "With statistically significant outcomes from a well-powered, multicenter randomized controlled trial, Nexpowder(TM) demonstrates clinically meaningful benefit beyond current standard therapies. These results not only reinforce the scientific validity of our platform, but also suggest a potential paradigm shift in the management of upper GI bleeding. We believe this data will support broader global adoption and inform future guideline development.

"Nexpowder(TM) is currently distributed in the United States and Europe through a global partnership with Medtronic. Nextbiomedical continues to expand its post-market clinical program in key regions to support broader use across indications and geographies.

View original content to download multimedia:https://www.prnewswire.com/news-releases/nextbiomedical-publishes-landmark-study-in-gut-demonstrating-nexpowder-significantly-reduces-rebleeding-after-endoscopic-hemostasis-302466629.html

SOURCE NEXTBIOMEDICAL CO., LTD.